Ironwood Pharmaceuticals IRWD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's cash & equivalents?
- Ironwood Pharmaceuticals (IRWD) reported cash & equivalents of $220.47M in Q1 2026.
- How has Ironwood Pharmaceuticals's cash & equivalents changed year-over-year?
- Ironwood Pharmaceuticals's cash & equivalents increased by 103.2% year-over-year, from $108.48M to $220.47M.
- What is the long-term trend for Ironwood Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's cash & equivalents has grown at a -9.9% compound annual growth rate (CAGR), from $362.56M to $215.46M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.